Streetbeat News

Stock Prices

ALZN

Alzamend Neuro Inc (NASDAQ:ALZN) has submitted an investigational new drug (IND) application to the FDA for a Phase IIA clinical study of AL001 for the treatment of major depressive disorder (MDD). AL001 is a novel lithium-delivery system that could deliver the benefits of marketed lithium salts while mitigating associated toxicities. The company aims to start a Phase IIA study following the FDA's approval. ALZN shares are down 0.55% at $0.20 premarket.

Portfolio Pulse from Akanksha Bakshi

October 23, 2023 | 11:31 am

AMZN

GOOGL

META

MSFT

TSLA

The new trading week is expected to face challenges due to earnings concerns, fears of rate hikes, and geopolitical tensions. Major corporations including Alphabet, Microsoft, Meta Platforms, and Amazon are set to release their earnings reports this week. Surging bond yields are expected to unsettle investors as the yield on the 10-year Treasury note has surpassed 5%. Last week, major stock indices experienced a decline due to robust economic data driving bond yields higher. The release of disappointing earnings reports, including that of Tesla, compounded concerns about corporate profit growth.

Portfolio Pulse from Shanthi Rexaline

October 23, 2023 | 11:27 am

ELS

B of A Securities analyst Jeffrey Spector has downgraded Equity Lifestyle Props (NYSE:ELS) from Buy to Neutral and lowered the price target from $70 to $64.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:23 am

VERV

Verve Therapeutics has received clearance from the FDA for its Investigational New Drug application for VERVE-101 in patients with heterozygous familial hypercholesterolemia. This has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:22 am

HARP

Harpoon Therapeutics has announced a private placement of up to $150 million. The funds will be used to advance the company's pipeline of T cell engagers.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:19 am

SHAK

Barclays analyst Jeffrey Bernstein has maintained an Equal-Weight rating on Shake Shack (NYSE:SHAK) and lowered the price target from $72 to $59.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:18 am

EGLX

Enthusiast Gaming has announced its intention to voluntarily delist from Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:17 am

PINS

Pinterest shares are trading higher following an upgrade from Stifel from Hold to Buy.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:15 am

WBA

Walgreens Boots Alliance's stock has been upgraded from Neutral to Overweight by JP Morgan, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 11:14 am

CVX

HES

Chevron Corp (NYSE:CVX) has agreed to acquire Hess Corp (NYSE:HES) in an all-stock transaction valued at $53 billion, or $171 per share, representing a 10.3% premium. The total enterprise value of the deal, including debt, is $60 billion. The acquisition is expected to diversify CVX's portfolio and enhance production and free cash flow. The deal is expected to close in H1 2024, subject to HES' shareholder approval and regulatory conditions.

Portfolio Pulse from Lekha Gupta

October 23, 2023 | 11:11 am